ROIV Stock Summary and Trading Ideas (Roivant Sciences Ltd. - Common Shares | NASDAQ:ROIV)

Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.

Roivant Sciences Ltd. - Common Shares trades on the NASDAQ stock market under the symbol ROIV.

As of September 16, 2026, ROIV stock price climbed to $39.57 with 5,462,769 million shares trading.

ROIV has a beta of 0.71, meaning it tends to be less sensitive to market movements. ROIV has a correlation of 0.06 to the broad based SPY ETF.

ROIV has a market cap of $28.59 billion. This is considered a Large Cap stock.

Last quarter Roivant Sciences Ltd. - Common Shares reported $1 million in Revenue and -$.34 earnings per share. This fell short of revenue expectation by $-903,840 and exceeded earnings estimates by $.03.

In the last 3 years, ROIV traded as high as $42.50 and as low as $8.25.

The top ETF exchange traded funds that ROIV belongs to (by Net Assets): VTI, VB, VBK, XMMO, VXF.

ROIV has outperformed the market in the last year with a price return of +179.1% while the SPY ETF gained +15.4%. ROIV has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +30.1% and +15.8%, respectively, while the SPY returned +0.7% and -1.5%, respectively.

ROIV support price is $38.52 and resistance is $40.48 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ROIV shares will trade within this expected range on the day.